Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Myriam Paredes

Nurse Practitioner Fords, NJ Nurse Practitioner

NPI 1649863028 CMS profile 10435314

408 New Brunswick Ave, Fords, NJ 08863

Open in the dashboard

General payments

$4,342

145 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Myriam Paredes of Fords, NJ is reported in the CMS Open Payments database as having received $4,342 across 145 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,265 48
2024 General $801 27
2023 General $1,506 34
2022 General $770 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Myriam Paredes
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Myriam Paredes were reported at $1,265. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Myriam Paredes Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $770 $152 $48–$470 $149
2023 $1,506 $166 $54–$529 $160
2024 $801 $173 $55–$556 $164
2025 $1,265 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,149 23 payments
  2. Novo Nordisk Inc $1,018 32 payments
  3. AstraZeneca Pharmaceuticals LP $494 12 payments
  4. Amgen Inc. $449 19 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $347 12 payments
  6. Lilly USA, LLC $306 20 payments
  7. Novartis Pharmaceuticals Corporation $154 6 payments
  8. AbbVie, Inc. $115 1 payment
  9. VBI Vaccines (Delaware) Inc. $57 4 payments
  10. RedHill Biopharma Inc. $53 4 payments
  11. Other $199 12 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,342 145 payments
Products named General payments · program years 2022–2025
  1. Ozempic $484 23 payments
  2. RYBELSUS $463 18 payments
  3. AREXVY $388 5 payments
  4. FARXIGA $359 9 payments
  5. Wegovy $300 5 payments
  6. REPATHA $268 14 payments
  7. JARDIANCE $257 6 payments
  8. TRELEGY ELLIPTA $238 11 payments
  9. MOUNJARO $227 15 payments
  10. Otezla $203 15 payments
  11. Other $1,232 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

3,103

Median for Nurse Practitioner: 389

Drug cost

$235,504

Median for Nurse Practitioner: $21,885

Branded share of claims

20.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 43 $55,422
Ozempic Semaglutide Brand 34 $37,041
Januvia Sitagliptin Phosphate Brand 32 $35,639
Rybelsus Semaglutide Brand 13 $28,417
Eliquis Apixaban Brand 14 $18,170
Tradjenta Linagliptin Brand 13 $11,439
Farxiga Dapagliflozin Propanediol Brand 11 $10,084
Atorvastatin Calcium Generic 239 $3,195
Humalog Kwikpen U-100 Insulin Lispro Brand 11 $2,939
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 27 $2,112

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $252
$252 — —
Repatha
  • Amgen Inc. $138
$138 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $132
$132 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $47
  • Lilly USA, LLC $16
$63 43 —
Ozempic
  • Novo Nordisk Inc $59
$59 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

145 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record